Literature DB >> 29444900

Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.

Sahir Kalim1, Ron Wald2, Andrew T Yan3, Marc B Goldstein2, Mercedeh Kiaii4, Dihua Xu1, Anders H Berg5, Clary Clish6, Ravi Thadhani1, Eugene P Rhee7,6,8, Jeffrey Perl2.   

Abstract

BACKGROUND AND OBJECTIVES: In-center, extended duration nocturnal hemodialysis has been associated with variable clinical benefits, but the effect of extended duration hemodialysis on many established uremic solutes and other components of the metabolome is unknown. We determined the magnitude of change in metabolite profiles for patients on extended duration nocturnal hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a 52-week prospective, observational study, we followed 33 patients receiving conventional thrice weekly hemodialysis who converted to nocturnal hemodialysis (7-8 hours per session, three times per week). A separate group of 20 patients who remained on conventional hemodialysis (3-4 hours per session, three times per week) served as a control group. For both groups, we applied liquid chromatography-mass spectrometry-based metabolite profiling on stored plasma samples collected from all participants at baseline and after 1 year. We examined longitudinal changes in 164 metabolites among those who remained on conventional hemodialysis and those who converted to nocturnal hemodialysis using Wilcoxon rank sum tests adjusted for multiple comparisons (false discovery rate <0.05).
RESULTS: On average, the nocturnal group had 9.6 hours more dialysis per week than the conventional group. Among 164 metabolites, none changed significantly from baseline to study end in the conventional group. Twenty-nine metabolites changed in the nocturnal group, 21 of which increased from baseline to study end (including all branched-chain amino acids). Eight metabolites decreased after conversion to nocturnal dialysis, including l-carnitine and acetylcarnitine. By contrast, several established uremic retention solutes, including p-cresol sulfate, indoxyl sulfate, and trimethylamine N-oxide, did not change with extended dialysis.
CONCLUSIONS: Across a wide array of metabolites examined, extended duration hemodialysis was associated with modest changes in the plasma metabolome, with most differences relating to metabolite increases, despite increased dialysis time. Few metabolites showed reduction with more dialysis, and no change in several established uremic toxins was observed.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  4-cresol sulfate; Acetylcarnitine; Amino Acids, Branched-Chain; Carnitine; Chromatography, Liquid; Control Groups; Cresols; Humans; Indican; Mass Spectrometry; Metabolome; Methylamines; Oxides; Prospective Studies; Statistics, Nonparametric; Sulfates; Sulfuric Acid Esters; hemodialysis; metabolomics; nocturnal dialysis; renal dialysis; trimethylamine; uremic toxins

Mesh:

Substances:

Year:  2018        PMID: 29444900      PMCID: PMC5967674          DOI: 10.2215/CJN.08790817

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease.

Authors:  Ron Wald; Marc B Goldstein; Jeffrey Perl; Mercedeh Kiaii; Darren Yuen; Rachel M Wald; Ziv Harel; Jordan J Weinstein; Baruch Jakubovic; Howard Leong-Poi; Anish Kirpalani; Jonathon Leipsic; Niki Dacouris; Myles Wolf; Andrew T Yan
Journal:  Can J Cardiol       Date:  2015-07-09       Impact factor: 5.223

2.  In-center hemodialysis six times per week versus three times per week.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger
Journal:  N Engl J Med       Date:  2010-11-20       Impact factor: 91.245

Review 3.  US Renal Data System 2013 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Areef Ishani; Kirsten Johansen; Bertram L Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Yan Hu; Allyson Kats; Shuling Li; Suying Li; Julia Maloney; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Eric Weinhandl; Hui Xiong; Akeem Yusuf; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Delaney Berrini; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2014-01       Impact factor: 8.860

4.  The role of EUTox in uremic toxin research.

Authors:  Raymond Vanholder; Omar Abou-Deif; Angel Argiles; Ulrich Baurmeister; Joachim Beige; Peter Brouckaert; Philippe Brunet; Gerald Cohen; Peter Paul De Deyn; Tilman B Drüeke; Danilo Fliser; Griet Glorieux; Stefan Herget-Rosenthal; Walter H Hörl; Joachim Jankowski; Achim Jörres; Ziad A Massy; Harald Mischak; Alessandra F Perna; Juan Mariano Rodriguez-Portillo; Goce Spasovski; Bernd G Stegmayr; Peter Stenvinkel; Paul J Thornalley; Christoph Wanner; Andrzej Wiecek
Journal:  Semin Dial       Date:  2009 Jul-Aug       Impact factor: 3.455

5.  Reduction of carbamylated albumin by extended hemodialysis.

Authors:  Jeffrey Perl; Sahir Kalim; Ron Wald; Marc B Goldstein; Andrew T Yan; Nazanin Noori; Mercedeh Kiaii; Julia Wenger; Christopher Chan; Ravi I Thadhani; S Ananth Karumanchi; Anders H Berg
Journal:  Hemodial Int       Date:  2016-06-21       Impact factor: 1.812

6.  Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study.

Authors:  Ercan Ok; Soner Duman; Gulay Asci; Murat Tumuklu; Ozen Onen Sertoz; Meral Kayikcioglu; Huseyin Toz; Siddik M Adam; Mumtaz Yilmaz; Halil Zeki Tonbul; Mehmet Ozkahya
Journal:  Nephrol Dial Transplant       Date:  2010-12-09       Impact factor: 5.992

7.  Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.

Authors:  Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

8.  Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate.

Authors:  Orlando Camacho; Maria Carmela Rosales; Tariq Shafi; Jonathan Fullman; Natalie S Plummer; Timothy W Meyer; Tammy L Sirich
Journal:  Nephrol Dial Transplant       Date:  2016-05-17       Impact factor: 5.992

Review 9.  Future Avenues to Decrease Uremic Toxin Concentration.

Authors:  Raymond C Vanholder; Sunny Eloot; Griet L R L Glorieux
Journal:  Am J Kidney Dis       Date:  2015-10-21       Impact factor: 8.860

10.  A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

Authors:  Sahir Kalim; Clary B Clish; Julia Wenger; Sammy Elmariah; Robert W Yeh; Joseph J Deferio; Kerry Pierce; Amy Deik; Robert E Gerszten; Ravi Thadhani; Eugene P Rhee
Journal:  J Am Heart Assoc       Date:  2013-12-05       Impact factor: 5.501

View more
  13 in total

1.  Blood Microbiome in CKD: Should We Care?

Authors:  Robert D Mair; Tammy L Sirich
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-08       Impact factor: 8.237

2.  Intensive Hemodialysis Fails to Reduce Plasma Levels of Uremic Solutes.

Authors:  Tammy L Sirich; Timothy W Meyer
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-14       Impact factor: 8.237

Review 3.  Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.

Authors:  Ignacio Portales-Castillo; Jerry Yee; Hiroshi Tanaka; Andrew Z Fenves
Journal:  Kidney360       Date:  2020-10-21

4.  Novel Approaches for the Removal of Uremic Solutes.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-14       Impact factor: 10.614

Review 5.  Avenues for post-translational protein modification prevention and therapy.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Mol Aspects Med       Date:  2022-02-25

Review 6.  Protein carbamylation in end stage renal disease: is there a mortality effect?

Authors:  Sahir Kalim
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-11       Impact factor: 2.894

7.  Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.

Authors:  Nilaksh Gupta; Jennifer A Buffa; Adam B Roberts; Naseer Sangwan; Sarah M Skye; Lin Li; Karen J Ho; John Varga; Joseph A DiDonato; W H Wilson Tang; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

8.  Optimized vs. Standard Automated Peritoneal Dialysis Regimens (OptiStAR): study protocol for a randomized controlled crossover trial.

Authors:  Karin Bergling; Javier de Arteaga; Fabián Ledesma; Carl Mikael Öberg
Journal:  Pilot Feasibility Stud       Date:  2020-06-10

Review 9.  Uremic Toxin Clearance and Cardiovascular Toxicities.

Authors:  Robert D Mair; Tammy L Sirich; Timothy W Meyer
Journal:  Toxins (Basel)       Date:  2018-06-02       Impact factor: 4.546

10.  Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study.

Authors:  Yan Chen; Leila R Zelnick; Ke Wang; Andrew N Hoofnagle; Jessica O Becker; Chi-Yuan Hsu; Harold I Feldman; Rupal C Mehta; James P Lash; Sushrut S Waikar; Tariq Shafi; Stephen L Seliger; Michael G Shlipak; Mahboob Rahman; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2020-03-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.